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Key messages
 ► How does interstitial lung disease (ILD)- specific 
quality of life in systemic sclerosis- associated inter-
stitial lung disease (SSc- ILD) compare with idiopath-
ic pulmonary fibrosis (IPF)?
 ► Unadjusted ILD- specific quality of life as measured 
by the Kings Brief Interstitial Lung Disease (K- BILD) 
Questionnaire was better in SSc- ILD than in IPF, but 
this difference appeared to be driven primarily by 
better lung function among patients with SSc- ILD.
 ► These data highlight the importance of lung function 
impairment in ILD- specific quality of life, and sup-
port the use of the K- BILD Questionnaire to assess 
disease- specific quality of life in systemic sclerosis- 
associated ILD.
AbstrAct
Introduction Idiopathic pulmonary fibrosis (IPF) and 
systemic sclerosis- associated interstitial lung disease 
(SSc- ILD) are fibrotic ILDs with divergent disease 
populations. Little is known about health- related quality of 
life (HRQL) in SSc- ILD relative to IPF.
Methods We used the Kings Brief Interstitial Lung Disease 
Questionnaire (K- BILD) to compare HRQL in a cross- 
sectional study of 57 patients with IPF and 29 patients with 
SSc- ILD. Analysis of covariance was used to adjust for age, 
gender and lung function.
results The unadjusted mean K- BILD score was 63.1 
(95% CI 57.1 to 69.1) among patients with SSc- ILD, 
as compared with 54.7 (51.8–57.5) among those with 
IPF (p=0.005). However, this difference in HRQL was 
attenuated after adjustment for age, gender and lung 
function. In a multivariable model, only forced vital capacity 
was associated with K- BILD scores. K- BILD scores were 
correlated with both forced vital capacity and with other 
relevant HRQL measures, regardless of ILD diagnosis.
Discussion Patients with SSc- ILD may have better 
ILD- specific quality of life than patients with IPF, but this 
difference appears to be driven primarily by better lung 
function. These results underscore the impact of lung 
function on HRQL in fibrotic ILD and the utility of K- BILD to 
assess HRQL in SSc- ILD.
IntroDuctIon
Interstitial lung disease (ILD) is associated 
with reduced health- related quality of life 
(HRQL).1 2 While idiopathic pulmonary 
fibrosis (IPF) has been considered the arche-
typal fibrotic ILD, it is increasingly recognised 
that other ILDs may have a progressive fibrotic 
phenotype in some patients.3 Such patients 
may have common biological and clinical 
characteristics independent of underlying 
diagnosis, which has provided rationale for 
several recent trials of antifibrotic therapy in 
non- IPF ILDs.4–6 Systemic sclerosis- associated 
ILD (SSc- ILD) has recently become the 
second form of ILD, in addition to IPF, for 
which the antifibrotic drug nintedanib has 
been approved in the USA, Canada and 
Europe.
However, compared with IPF, SSc- ILD is 
a manifestation of a multisystemic disease 
affecting a younger population.7 Although 
individual disease trajectories vary, disease 
progression is slower and mortality lower in 
general among patients with SSc- ILD.8 While 
overall HRQL is impaired in SSc,9 there is a 
paucity of studies of HRQL using ILD- specific 
tools in SSc, and the extent to which ILD- 
related HRQL in SSc- ILD differs from IPF is 
not well understood.
ILD- specific HRQL instruments, such as 
the Kings Brief Interstitial Lung Disease 
(K- BILD) Questionnaire, have been devel-
oped and validated across a range of ILDs.10 
Disease- specific as compared with generic 
tools may be more sensitive for identifying 
impairment and assessing change in HRQL. 
Assessing differences in HRQL between 
different fibrotic ILDs is important to under-
stand the patient populations for whom anti-
fibrotic therapy is relevant, and potentially to 
determine the effects of such treatment.
Because IPF is more frequently progres-
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Age 71 (9) 59 (12)
Female 16 (28) 23 (79)
FVC (% predicted) 73 (18) 92 (20)
DLCO (% predicted) 45 (14) 57 (21)
Long- term oxygen use 8 (14) 4 (15)
Nintedanib treatment 34 (60) 0 (0)
Pirfenidone treatment 19 (33) 0 (0)
Corticosteroid treatment 4 (7) 3 (10)
Immunosuppressive treatment 0 (0) 16 (55)
EQ- 5D 0.712 (0.232) 0.640 (0.252)
Leicester Cough Questionnaire 
(total score)
16.3 (4.2) 17.3 (4.1)
St. Georges Respiratory 
Questionnaire (total score)
43.6 (22.4) 38.2 (23.2)
Presented as mean (SD) or n (%).
DLCO, diffusing capacity of lung for carbon monoxide; EQ- 5D, 
EuroQol- 5D; FVC, forced vital capacity; ILD, interstitial lung disease; 
IPF, idiopathic pulmonary fibrosis; SSc, systemic sclerosis.
is associated with greater impairment in ILD- specific 
HRQL than SSc- ILD. We used the K- BILD to assess ILD- 
specific HRQL in patients with SSc- ILD as compared with 
IPF.
MethoDs
study design and patients
This was a cross- sectional study enrolling adult patients 
aged ≥18 years with IPF and SSc- ILD during ambulatory 
visits at three university hospitals in Norway. Diagnoses 
were based on current consensus criteria for IPF11 and 
SSc12 at the time of the study. Exclusion criteria included 
chronic lung diseases other than IPF or SSc- ILD, and 
inability to understand or complete self- administered 
questionnaires in Norwegian. As not all patients with 
SSc have ILD, the presence of ILD was verified by 
review of both the medical record and chest CT at the 
time of enrolment. Consecutive eligible patients were 
approached for inclusion; no patients declined inclu-
sion. Sample size considerations are given in more detail 
in the online supplementary file. A total of 87 patients 
provided written informed consent and were included 
in the original study. One patient did not complete the 
K- BILD Questionnaire, leaving 86 patients included in 
the current analysis.
K-bILD and other quality of life measures
The development of the Norwegian version of the 
K- BILD Questionnaire is summarised in online supple-
mentary figure 1. The original validated English version 
of the K- BILD10 was used as a basis for developing the 
Norwegian version. After consultation with the original 
developers of K- BILD, the organisation Mapi Research 
Trust (Lyon, France) conducted the translation as per 
the developer’s instructions. Briefly, the questionnaire 
was first translated into Norwegian by two independent 
bilingual translators. These two independent translations 
were then reconciled. This reconciled version was then 
vetted through a process of back- translation to English 
and review by the original developers of the instrument as 
well as independent quality assurers for content validity. 
This vetted, reconciled Norwegian version was subse-
quently subjected to review by key Norwegian experts 
within the field of ILD, before linguistic testing with five 
patients using cognitive interviews, leading to the final 
Norwegian version of K- BILD. In addition to the K- BILD, 
patients completed the St. Georges Respiratory Ques-
tionnaire (SGRQ),13 Leicester Cough Questionnaire 
(LCQ)14 and EuroQol- 5D (EQ- 5D) index.15
statistical analysis
K- BILD total and domain scores were calculated using 
the logit- based method. Scores range from 0 to 100 with 
higher scores indicating better HRQL.16 Mean unadjusted 
K- BILD scores were compared using t- tests. Analysis of 
covariance was used to adjust for age, gender, forced vital 
capacity (FVC) and diffusing capacity of lung for carbon 
monoxide (DLCO). Covariates were prespecified and 
selected based on known or clinically plausible effects 
on ILD- specific HRQL. No form of variable selection was 
used in the modelling process. Linear models were used 
to assess the relationships between K- BILD scores, lung 
function and other HRQL measures. Interaction terms 
assessed whether relationships differed by diagnosis.
Patient and public involvement
Patients or the public were not directly involved in the 
design, conduct, reporting or dissemination plans of our 
research.
resuLts
Fifty- seven patients with IPF and 29 patients with SSc- ILD 
were included between September 2017 and October 
2018. Compared with patients with IPF, those with SSc- 
ILD were younger (mean age 59 vs 71 years), predomi-
nantly female (79% vs 28%), and had better lung func-
tion (FVC 87% vs 73% of predicted, DLCO 57% vs 45% 
of predicted). The majority of patients with IPF were 
treated with pirfenidone or nintedanib, whereas over 
half of those with SSc- ILD were treated with immunosup-
pressive drugs (table 1).
The mean K- BILD score was 63.1 (95% CI 57.1 to 69.1) 
among patients with SSc- ILD, as compared with 54.7 (95% 
CI 51.8 to 57.5) among those with IPF (p=0.005), indi-
cating better ILD- related HRQL in SSc- ILD (figure 1). 
After adjustment for age, gender, FVC and DLCO, the 
difference was slightly attenuated, with adjusted mean 
K- BILD score 62.6 (95% CI 57.0 to 68.2) in SSc- ILD and 
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Figure 1 Kings Brief Interstitial Lung Disease (K- BILD) 
total and domain scores. Unadjusted mean total and 
domain K- BILD scores are shown for the idiopathic 
pulmonary fibrosis (IPF) and systemic sclerosis- associated 
interstitial lung disease (SSc- ILD) groups below the X- 
axis, with values for individual patients shown in the plot. 
The box and whiskers plots show median, 25th and 75th 
percentiles, minimum and maximum values. P values 
shown are for two- sample t- test comparisons between IPF 
and SSc- ILD.
Table 2 Adjusted K- BILD total and domain scores
IPF SSc- ILD P value
Total score 55.5 (51.9 to 59.1) 62.6 (57.0 to 68.2) 0.061
Breathlessness 41.5 (36.8 to 46.2) 48.5 (41.3 to 55.7) 0.141
Chest symptoms 66.2 (60.1 to 72.3) 71.7 (62.5 to 81.0) 0.362
Psychological 55.5 (50.2 to 60.8) 71.9 (63.8 to 80.1) 0.003*
. Estimates are derived from analysis of covariance models, and represent the marginal mean K- BILD total or domain score at the mean value 
for each adjustment covariate (age, gender, FVC and DLCO). Presented as adjusted mean (95% CI).
*Remains significant after adjustment for multiple comparisons using the Bonferroni- Holm method (nominal p value 0.003 is less than the 
critical Bonferroni- Holm value of 0.0125).
DLCO, diffusing capacity of lung for carbon monoxide; FVC, forced vital capacity; ILD, interstitial lung disease; IPF, idiopathic pulmonary 
fibrosis; K- BILD, Kings Brief Interstitial Lung Disease; SSc, systemic sclerosis.
K- BILD domain scores indicated that patients with IPF 
had greater breathlessness compared with patients with 
SSc- ILD (figure 1), but this difference was not significant 
after multivariable adjustment (table 2). Psychological 
domain scores indicated better psychological QOL in 
SSc- ILD, and this difference remained significant after 
multivariable adjustment.
Associations between K- BILD total score, lung function 
and other HRQL measures are shown in figure 2. There 
was a significant association between K- BILD total score 
and both FVC and DLCO, with higher FVC or DLCO asso-
ciated with better HRQL. K- BILD total scores correlated 
with other HRQL measures, including the SGRQ, LCQ 
and EQ- 5D index. None of these relationships differed 
by diagnosis (interaction p>0.05 for all).
In a multivariable model including age, gender, FVC 
and DLCO, only FVC was significantly associated with 
total K- BILD scores (online supplementary table 2).
DIscussIon
ILD- specific HRQL assessed by K- BILD appears to be 
similar between patients with IPF and SSc- ILD after 
adjustment for age, gender and lung function, with 
restrictive lung physiology as measured by FVC strongly 
correlated with HRQL in both disease groups. However, 
unadjusted ILD- specific HRQL was better in SSc- ILD 
than in IPF, suggesting that younger age and better lung 
function may contribute to better HRQL among patients 
with SSc- ILD. Patients with SSc- ILD had better psycholog-
ical quality of life than those with IPF, independent of age 
and lung function differences.
Compared with the mixed ILD population in which the 
K- BILD was developed,10 patients with IPF in our study 
had generally poorer HRQL, despite only slightly lower 
lung function. Patients with IPF enrolled in a national 
registry in Sweden had similarly poor HRQL as assessed 
by the K- BILD.17 Taken together, these findings suggest 
that IPF may be associated with especially poor HRQL 
compared with other ILDs. By contrast, K- BILD scores 
among patients with SSc- ILD in our study were similar to 
those in previous mixed ILD populations.10
Even after adjustment, psychological HRQL remained 
markedly better in SSc- ILD. These data suggest that 
disease- specific factors, rather than severity of lung 
disease, may be most related to psychological HRQL in 
the ILD population. Our data cannot offer a definite 
explanation for this finding, but it is notable that several 
of the K- BILD items that comprise the psychological 
domain refer to anxiety, concern or expectations related 
to disease worsening. In this context, it is possible that 
the relatively widespread knowledge about poor prog-
nosis and risk of progression in IPF may have negative 
impact on psychological HRQL among patients, above 
and beyond their actual objective disease severity at a 
given time.
Compared with IPF, SSc- ILD is a multisystem disorder, 
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Figure 2 Relationships between Kings Brief Interstitial Lung Disease (K- BILD) total score, lung function and other health- 
related quality of life measures. Plots show the relationship between the given lung function or health- related quality of life 
(HRQL) measure and K- BILD total score in the overall study population. There were no significant statistical interactions 
with diagnosis. Regression coefficients therefore represent the univariable association between K- BILD total score and the 
given measure in the overall study population, and correspond with the regression line shown. Individual data points are 
presented separately for each diagnosis for illustrative purposes. DLCO, diffusing capacity of lung for carbon monoxide; EQ- 
5D, EuroQol; FVC, forced vital capacity; IPF, idiopathic pulmonary fibrosis; LCQ, Leicester Cough Questionnaire; SGRQ, St. 
George Respiratory Questionnaire; SSc- ILD, systemic sclerosis- associated interstitial lung disease.
HRQL substantially. Having been developed as an ILD- 
specific instrument, the K- BILD is unlikely to capture 
the overall impact of SSc on HRLQ. While the K- BILD 
items refer explicitly to the impact of lung disease, other 
SSc manifestations with overlapping symptoms, such as 
pulmonary hypertension, could plausibly affect patients’ 
responses to the items. On the other hand, patients with 
IPF may have secondary pulmonary hypertension or 
other, unrelated, cardiopulmonary comorbidities that 
impact patient responses.
SSc- ILD is the second form of ILD other than IPF 
with specific approved therapy, with the SENSCIS trial 
demonstrating a benefit of nintedanib in reducing the 
rate of decline in FVC.4 In this context, tools to help 
understand disease- specific HRQL in SSc- ILD will be 
increasingly important in understanding disease char-
acteristics, progression and the effects of treatment in 
clinical practice. In our study, K- BILD scores correlated 
as expected with FVC and other validated HRQL instru-
ments commonly used in ILD, including the SGRQ, LCQ 
and EQ- 5D. These associations were largely independent 
of diagnosis, and support the validity of the K- BILD as 
an instrument to assess HRQL also among patients with 
SSc- ILD.
Our study has several limitations. First, the cross- 
sectional design precludes the assessment of K- BILD as 
a tool for longitudinal assessment of ILD- specific HRQL 
over time in SSc- ILD. An established tool for assessing 
changes in ILD- specific HRQL over time would be partic-
ularly helpful for evaluating emerging therapies, and 
represents a pressing need for future patient- reported 
outcome research. Second, the study enrolled only from 
academic centres; however, in Norway, the vast majority 
of patients with IPF and SSc- ILD are managed at such 
centres, such that our cohort is likely to be representative 
of the overall Norwegian patient population with these 
conditions. Finally, available treatments for both IPF and 
SSc are associated with substantial side effects, which our 
study design did not allow us to investigate specifically. In 
particular, nearly all patients with IPF in the study were 
taking antifibrotic therapy, which did not allow the effects 
of such therapy to be separated from the main effect of 
IPF versus SSc, and no patients with SSc- ILD were on 
such therapy. In contrast, a large majority of patients with 
SSc- ILD, but no patients with IPF, were taking immuno-
suppressive medications. While the K- BILD items are 
specifically formulated to address the effects of the lung 
disease itself, the impact of treatment side effects is likely 
to contribute substantially to overall HRQL and should 
be a priority in future HRQL research in these disease 
populations.
concLusIons
HRQL as measured by K- BILD is similar in IPF and SSc- 
ILD after accounting for differences in age, sex and lung 
function. HRQL is associated with with restrictive lung 
physiology in both diseases. K- BILD correlates well with 
other relevant HRQL measures, and appears to be a 
useful instrument for measuring HRQL also in SSc- ILD. 
Further studies should compare change in HRQL as 
measured by K- BILD over time in SSc- ILD and IPF.
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